Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.059
Neutral
RSI(14)
37.258
Neutral
STOCH(KDJ)(9,3,3)
16.370
Sell
ATR(14)
0.116
High Vlolatility
CCI(14)
-98.041
Neutral
Williams %R
90.411
Oversold
TRIX(12,20)
-1.030
Sell
StochRSI(14)
0.000
Sell
Search
Cibus Inc
CBUSAdd to Watchlist
1.310USD
-0.100-7.09%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
71.17MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Cibus Inc
Currency: USD Updated: 2026-05-15Key Insights
Cibus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 136 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cibus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cibus Inc Highlights
StrengthsRisks
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 100.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.64M.
Fairly Valued
The company’s latest PE is -0.74, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.20M shares, decreasing 16.16% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 69.40K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.10.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
14.667
Target Price
+940.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Cibus Inc is 4.96, ranking 204 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.68M, representing a year-over-year increase of 62.57%, while its net profit experienced a year-over-year increase of 54.74%.
Score
Financials
4.37
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.91
Operational Efficiency
2.84
Growth Potential
3.61
Shareholder Returns
7.08
Cibus Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Cibus Inc is 8.68, ranking 13 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.74, which is -89.38% below the recent high of -0.08 and -205.90% above the recent low of -2.27.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 136/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Cibus Inc is 7.33, ranking 137 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 15.50, with a high of 25.00 and a low of 1.60.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
14.667
Target Price
+1019.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Cibus Inc
CBUS
3
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Cibus Inc is 3.65, ranking 195 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.54 and the support level at 1.18, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.397
Sell
MA10
1.455
Sell
MA20
1.454
Sell
MA50
2.038
Sell
MA100
2.172
Sell
MA200
1.799
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Cibus Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 16.60%, representing a quarter-over-quarter decrease of 43.24%. The largest institutional shareholder is James Simons, holding a total of 69.40K shares, representing 0.09% of shares outstanding, with 32.27% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cibus Inc is 1.90, ranking 171 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.65. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.64
VaR
+10.26%
240-Day Maximum Drawdown
+68.89%
240-Day Volatility
+108.84%
Return
Best Daily Return
60 days
+19.84%
120 days
+41.74%
5 years
+90.25%
Worst Daily Return
60 days
-25.78%
120 days
-25.78%
5 years
-34.32%
Sharpe Ratio
60 days
-2.07
120 days
+0.69
5 years
-0.33
Risk Assessment
Maximum Drawdown
240 days
+68.89%
3 years
+95.14%
5 years
+99.46%
Return-to-Drawdown Ratio
240 days
-0.78
3 years
-0.30
5 years
-0.20
Skewness
240 days
+0.19
3 years
+0.43
5 years
+1.76
Volatility
Realised Volatility
240 days
+108.84%
5 years
+129.82%
Standardised True Range
240 days
+13.39%
5 years
+177.39%
Downside Risk-Adjusted Return
120 days
+111.58%
240 days
+111.58%
Maximum Daily Upside Volatility
60 days
+91.69%
Maximum Daily Downside Volatility
60 days
+96.92%
Liquidity
Average Turnover Rate
60 days
+1.13%
120 days
+0.87%
5 years
--
Turnover Deviation
20 days
-9.87%
60 days
+37.21%
120 days
+5.22%
Peer Comparison
Healthcare Equipment & Supplies
Cibus Inc
CBUS
5.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
